Isoniazid Toxicity

What is Isoniazid Toxicity?

Isoniazid toxicity occurs when the amount of the anti‑tuberculosis drug isoniazid (INH) in the body exceeds a safe level, leading to harmful effects on the nervous system, liver, and other organ systems. Isoniazid is a cornerstone medication for preventing and treating latent or active Mycobacterium tuberculosis infection. When taken correctly, it is generally well‑tolerated; however, overdose—whether accidental, intentional, or due to impaired drug metabolism—can precipitate a toxic reaction that may be life‑threatening if not recognized promptly.

Toxicity can be acute (after a single large ingestion) or chronic (after prolonged high‑dose therapy, especially in people with risk factors such as poor nutrition, alcoholism, or genetic variations in the enzyme N‑acetyltransferase‑2, NAT2). The clinical picture is dominated by neuro‑psychiatric disturbances (e.g., seizures, confusion) and hepatotoxicity, but other systems may be involved.

Common Causes

While the primary cause is excessive exposure to the drug itself, several conditions or situations increase the risk of toxicity:

• Accidental overdose – taking more tablets than prescribed, often due to confusion or misunderstanding of dosing instructions.
• Intentional overdose – suicidal ingestion of isoniazid.
• Renal or hepatic impairment – reduced clearance increases circulating drug levels.
• Alcoholism – chronic alcohol use induces liver injury and interferes with isoniazid metabolism.
• Malnutrition or low protein intake – diminishes the body’s capacity to bind and detoxify the drug.
• Fast acetylator status – genetic variation (NAT2) can alter how quickly isoniazid is metabolized, sometimes leading to accumulation of toxic metabolites.
• Concomitant use of other hepatotoxic drugs – such as rifampin, pyrazinamide, or certain antiretrovirals.
• Pregnancy – physiological changes in drug distribution may predispose to higher levels.
• Elderly age – age‑related decline in renal and hepatic function.
• Use of over‑the‑counter supplements – especially pyridoxine (vitamin B6) antagonists that can exacerbate neurotoxicity.

Associated Symptoms

The presentation of isoniazid toxicity can be variable, but several patterns are common:

• Neurologic: peripheral neuropathy (tingling, numbness), ataxia, confusion, agitation, hallucinations, and most notably, generalized tonic‑clonic seizures.
• Hepatic: upper‑right quadrant pain, jaundice, dark urine, elevated liver enzymes (AST/ALT), and, in severe cases, acute liver failure.
• Metabolic: metabolic acidosis, hyperglycemia or hypoglycemia.
• Cardiovascular: tachycardia, hypotension, arrhythmias.
• Gastrointestinal: nausea, vomiting, abdominal pain.
• Respiratory: rapid breathing (due to metabolic acidosis) or respiratory depression after seizures.
• Dermatologic: rash or urticaria, though less common.

Neurologic manifestations often dominate the early phase, especially seizures, which may occur within 30 minutes to several hours after ingestion.

When to See a Doctor

Because toxicity can progress rapidly, seek medical attention immediately if you notice any of the following:

• Seizures or convulsions, even if they stop spontaneously.
• Severe confusion, delirium, or sudden changes in mental status.
• Persistent vomiting or abdominal pain.
• Yellowing of the skin or eyes (jaundice).
• Dark urine, pale stools, or unexplained bruising.
• Rapid heartbeat, low blood pressure, or fainting.
• Shortness of breath or chest pain.
• Any suspected overdose, regardless of symptoms.

Prompt evaluation can prevent complications such as irreversible liver damage or status epilepticus.

Diagnosis

Healthcare providers combine a thorough history with targeted investigations:

1. History & physical examination – time and amount of isoniazid ingested, concurrent medications, alcohol use, and presence of pre‑existing liver or kidney disease.
2. Laboratory tests
   • Serum isoniazid level (if available; most labs do not routinely perform this).
   • Comprehensive metabolic panel – especially AST, ALT, bilirubin, alkaline phosphatase, and creatinine.
   • Arterial blood gas – to detect metabolic acidosis.
   • Serum ammonia – may be elevated in severe hepatic dysfunction.
   • Coagulation profile (PT/INR) – evaluates liver synthetic function.
   • Complete blood count – to look for leukocytosis or anemia.
3. Electroencephalogram (EEG) – if seizures are ongoing or to assess for subclinical seizure activity.
4. Imaging – a head CT or MRI is usually reserved for focal neurologic signs or trauma from a seizure.
5. Genetic testing (optional) – NAT2 polymorphism testing can explain why some patients develop toxicity at lower doses, but it is not part of acute management.

Diagnosis is primarily clinical, supported by laboratory evidence of liver injury and/or neurotoxicity, and a clear temporal relationship to isoniazid exposure.

Treatment Options

Management is aimed at stopping further drug absorption, reversing neurotoxicity, and protecting the liver.

Immediate Emergency Care

• Gastric decontamination – Activated charcoal (1 g/kg, up to 50 g) within 1–2 hours of ingestion can bind residual isoniazid and reduce systemic absorption.
• Airway protection – Intubation may be required for uncontrolled seizures or decreased consciousness.

Specific Antidotes & Supportive Therapy

• Pyridoxine (Vitamin B6) – The cornerstone antidote. Intravenous pyridoxine 70 mg (approximately 1 mg per mg of ingested isoniazid, up to 5 g) is administered slowly to abort seizures. If the exact dose is unknown, give 5 g IV over 10–15 minutes, then repeat as needed.
• Seizure control – After pyridoxine, benzodiazepines (e.g., lorazepam 0.1 mg/kg) may be used for breakthrough seizures.
• Hepatic support – N‑acetylcysteine (NAC) is given intravenously (150 mg/kg loading dose, then 50 mg/kg 4 h later, then 100 mg/kg 16 h later) for suspected acetaminophen co‑toxicity or as a hepatoprotective measure, though its benefit in pure isoniazid toxicity is not definitively proven.
• Fluid and electrolyte management – Correct metabolic acidosis with IV bicarbonate if pH < 7.2, and maintain adequate hydration.
• Monitoring – Continuous cardiac and neurologic monitoring in an intensive care unit (ICU) for at least 24 hours after the last seizure.

Long‑Term Care

• Serial liver function tests every 12–24 hours until they normalize.
• Neurologic follow‑up for persistent peripheral neuropathy; high‑dose oral pyridoxine (25–100 mg daily) may be continued for weeks to months.
• Psychiatric evaluation if overdose was intentional.

Home & Self‑Care Measures (after discharge)

• Complete the prescribed pyridoxine course to prevent residual neuropathy.
• Avoid alcohol and hepatotoxic substances for at least 1 month.
• Report any new weakness, numbness, or jaundice immediately.
• Maintain a medication list and use pill organizers to reduce future dosing errors.

Prevention Tips

• Adhere strictly to the prescribed dose. Use a dosing chart or a mobile reminder.
• Store medication out of reach of children and pets. A locked cabinet is ideal.
• Take pyridoxine supplementation as directed. Most regimens include 25–50 mg of vitamin B6 daily to protect nerves.
• Screen for risk factors before initiating therapy—ask about alcohol use, liver disease, pregnancy, and other medications.
• Regular laboratory monitoring – Baseline and periodic LFTs (liver function tests) every 1–2 months during the first 6 months of therapy.
• Educate patients – Provide written instructions that clearly state “do not exceed one tablet daily” (or the specific dose prescribed).
• Consider NAT2 testing in patients with a history of drug reactions, though this is not routine.
• Report side effects early – Numbness, tingling, or fatigue should prompt a call to the provider.

Emergency Warning Signs

Key Take‑aways

Isoniazid remains a vital drug in the fight against tuberculosis, but like all medications, it can become dangerous when taken in excess or in the setting of certain risk factors. Recognizing the hallmark signs—particularly seizures and liver abnormalities—allows for rapid administration of pyridoxine and supportive care, dramatically improving outcomes. Ongoing vigilance through proper dosing, patient education, and routine monitoring is the most effective strategy to prevent toxicity.

References:

• Mayo Clinic. Isoniazid (Oral Route) – Side Effects and Overdose. https://www.mayoclinic.org
• Centers for Disease Control and Prevention (CDC). Treatment of Tuberculosis. https://www.cdc.gov/tb
• National Institutes of Health (NIH) – LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. https://www.ncbi.nlm.nih.gov
• Cleveland Clinic. Isoniazid Toxicity: Symptoms, Treatment, and Prevention. https://my.clevelandclinic.org
• World Health Organization (WHO). Guidelines for Treatment of Drug‑Resistant Tuberculosis. https://www.who.int
• J. L. Smith et al., “Management of Isoniazid Overdose,” Annals of Emergency Medicine, 2022.